Blueprint Medicines Competitors and Similar CompaniesClear all

Blueprint Medicines's competitors and similar companies include Deciphera Pharmaceuticals, Repare Therapeutics, Ohm Oncology and AstraZeneca United States.

	Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.	Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.	Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.	Ohm Oncology Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.	AstraZeneca United States AstraZeneca United States is a biopharmaceutical company.
Founding Date	Founding Date 2011	Founding Date 2003	Founding Date 2016	Founding Date 2015	Founding Date N/A
Type	Type Public	Type Public	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare drug development life sciences oncology	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology platform	Tags Manufacturing & Industrial biotech drug development oncology pharma	Tags Manufacturing & Industrial biotech drug development pharma
Locations	Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH	Locations Waltham, US HQ Lawrence, US	Locations Montréal, CA HQ Cambridge, US	Locations Austin, US HQ	Locations Wilmington, US HQ Gaithersburg, US
Employees	Employees 6552% increase	Employees 35037% increase	Employees 179	Employees 167% decrease	Employees N/A
Valuation ($)	Valuation ($) 5.3 b	Valuation ($) 2.2 b	Valuation ($) 152.4 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $508.8m (FY, 2024)	Revenue (est.) $163.4m (FY, 2023)	Revenue (est.) $51.1m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $20.2m (FY, 2024)	Cost of goods $3.7m (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $488.7m (FY, 2024)	Gross profit $159.6m (FY, 2023)	Gross profit $51.1m (FY, 2023)	Gross profit N/A	Gross profit N/A
Net income	Net income ($67.1m) (FY, 2024)	Net income ($194.9m) (FY, 2023)	Net income ($93.8m) (FY, 2023)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 1.7b	Total funding raised $ 714m	Total funding raised $ 150.5m	Total funding raised N/A	Total funding raised N/A